Page 74 - Michael Erman News Today

An authorization for that age group would be would be an important regulatory step toward reaching about 28 million children for inoculation, most of them back in school for in-person learning.

An authorization for that age group would be an important regulatory step toward reaching about 28 million children for inoculation, most of them back in school for in-person learning.

An authorization for that age group would be an important regulatory step toward reaching about 28 million children for inoculation, most of them back in school for in-person learning.

By Michael Erman NEW YORK (Reuters) - The U.S. Food and Drug Administration is considering authorizing a COVID-19 vaccine for children aged 5 to 11. The vaccine from Pfizer Inc and BioNTech SE has been available in the United States to kids aged 12 to 15 since May. Here is what you need to know about the vaccine and children: When will COVID-19 vaccines be available for 5- to 11-year-olds? The shots are likely to be available early November. The FDA will consider the recommendation of a committe...

An authorization for that age group would be would be an important regulatory step toward reaching about 28 million children for inoculation, most of them back in school for in-person learning.

Breaking News, Latest News and Current News from OANN.com. Breaking news and video. Latest Current News: U.S., World, Entertainment, Health, Business, Technology, Politics, Sports.

An authorization for that age group would be an important regulatory step toward reaching about 28 million children for inoculation, most of them back in school for in-person learning.

An authorization for that age group would be would be an important regulatory step toward reaching about 28 million children for inoculation, most of them back in school for in-person learning.

An authorization for that age group would be would be an important regulatory step toward reaching about 28 million children for inoculation, most of them back in school for in-person learning.

An authorization for that age group would be an important regulatory step toward reaching about 28 million children for inoculation, most of them back in school for in-person learning.